Illumina Ignites (ILMN)

Illumina Ignites

I figured Affymetrix's (Nasdaq: AFFX ) lackluster growth would extend to the entire laboratory supply industry, but that doesn't seem to be the case. Competitor Illumina (Nasdaq: ILMN ) smashed expectations on Tuesday.

The biochip maker saw revenue shoot up 69% year over year and 8% sequentially in the first quarter. Adjusted income was even more impressive, jumping 77% year over year.

Instrument sales were up 127% year over year and, while they tend to fetch a lower gross margin, they'll drive sales of higher-margin consumables that make the machines run in future quarters. The idea, made famous by Gillette, is used by great companies like Intuitive Surgical (Nasdaq: ISRG ) , and it certainly seems to be working for Illlumina -- consumables were up an equally impressive 63%.

Not only is the company selling more instruments, it's also making instruments that work faster -- eating more reagents per day than the slower machines could. Its newest offering, the iScan, is six times faster than its old BeadStation. Now, granted, most labs won't instantly have six times as many samples to run after upgrading to the iScan, but as the technology catches on, I think we'll see more iScans running at full speed.

While there's little not to like about Illumina's growth, its price compared to its peers still leaves something to be desired. Illumina is expecting revenue this year to come in between $515 million and $535 million -- about 5% more than Affymetrix's newly updated guidance -- yet investors are valuing Illumina at almost 6 times its competitor. Granted, Illumina is expecting revenue growth in the 40%-46% range this year, compared to Affymetrix's 8%-13%, but the difference in market caps still seems rather extreme.

For more Foolishness:

Best Odds in the Universe!
If you're interested in a 98.79% chance at beating the market... and a 70.84% chance at DOUBLING the market's return – Motley Fool Supernova could be just what you're looking for. And get this: We arrived at these odds from 10,000 random back-tested portfolios composed of Motley Fool Co-founder David Gardner's personal stock picks.

It's why David recently handpicked a small team of world-class portfolio managers. You see, he thinks these odds can get even better! And he'd like to prove it to you...

Simply enter your email address. And the answer to the question everybody is asking will be delivered to your inbox!

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.